medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2019, Number 2

<< Back

Rev Mex Patol Clin Med Lab 2019; 66 (2)

Polycystic ovary syndrome

Barba EJR

Language: Spanish
References: 67
Page: 107-123
PDF size: 355.35 Kb.


ABSTRACT

Polycystic ovarian syndrome is currently the most frequent endocrine alteration in reproductive women, which entails health implications for those who suffer from the endocrinological, metabolic, fertility and risk of seeing neoplasms. This pathology is characterized by the presence of menstrual disorders, clinical signs of hyperandrogenism as well as the presence of polycystic ovaries by ultrasound. There are different criteria to establish the diagnosis, being the laboratory fundamental for the recognition of this entity.


REFERENCES

  1. Aguirre MA, Benvenuto CG, Urrutia SMT. Calidad de vida en mujeres con síndrome de ovario poliquístico. Rev Chil Obstet Ginecol. 2005; 70 (2): 103-107.

  2. López-Rivero LP, Hernández-Marín I, Pascacio-Sarmiento H, Gordillo-Méndez K, Cadena-Alfaro GN, Madrid-Zavala RM. Correlación entre insulino-resistencia e hiperandrogenismo. Ginecol Obstet Mex. 2012; 80 (1): 30-35.

  3. Carazo-Hernández B, Lafalla-Bernad O, García-Simón R, Gascón-Mas E, Moreno-Romea E, Rojas-Pérez EB. Calidad de vida relacionada con la salud en mujeres con ovario poliquístico. Medisur. 2014; 12 (2): 408-415.

  4. Mercedes-Quillatupa N, Rabanal MK, Nora-Scaletti S, Rechkemmer-Prieto A, Rodríguez D. Características clínicas y bioquímicas de pacientes con síndrome de ovario poliquístico e infertilidad. Rev Per Ginecol Obstet. 2010; 56: 149-154.

  5. Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod. 2013; 28 (9): 2537-2544.

  6. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011; 26 (11): 3123-3129.

  7. Sir PT, Preisler RJ, Magendzo NA. Síndrome de ovario poliquístico. Diagnóstico y manejo. Rev Med Clin Condes. 2013; 24 (5): 818-826.

  8. Chiliquinga-Villacis S, Aguirre-Fernández R, Agudo-Gonzabay M, Chú-Lee A, Cuenca-Buele S. Criterios diagnósticos y tratamiento integral terapéutico del síndrome de ovarios poliquísticos. Rev Cubana Obstet Ginecol. 2017; 43 (3): 300-309.

  9. Borbón-Cordero MF, Robles-Quirós F. Síndrome de ovario poliquístico. Rev Cl EMed UCR. 2016; 1 (1): 134-137.

  10. Facio-Lince García A, Pérez-Palacio MI, Molina-Valencia JL, Martínez-Sánchez LM. Síndrome de ovario poliquístico y complicaciones metabólicas: más allá del exceso de andrógenos. Rev Chil Obstet Ginecol. 2015; 80 (6): 515-519.

  11. Allahbadia G, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertility Society Journal. 2011; 16: 19-37.

  12. Hincapié-Garaviño SM, Benavides-Quiñones AM, Botero-Barreneche E, Marín-Henao E, Rico-Rico LM. El Síndrome de ovario poliquístico y su relación con el ciclo vital de la mujer. CES Movimiento y Salud. 2014; 2 (2): 89-100.

  13. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18 (6): 618-637.

  14. Adali E, Yildizhan R, Kurdoglu M, Kolusari A, Edirne T, Sahin HG et al. The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res. 2008; 36 (6): 1188-1196.

  15. Silva VR. Síndrome de ovario poliquístico e infertilidad. Rev Med Clin Condes. 2010; 21 (3): 387-396.

  16. Melo AS, Vieira CS, Barbieri MA, Rosa-E-Silva AC, Silva AA, Cardoso VC et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum Reprod. 2010; 25 (8): 2124-2131.

  17. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27 (10): 3067-3073.

  18. Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG. 2010; 117 (2): 150-155.

  19. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33 (6): 981-1030.

  20. García-Romero de Tejada G, Escobar-Morreale HF. Hiperandrogenismo en la mujer diabética: rol de la resistencia insulínica y de la hiperinsulinemia. Endocrinol Nutr. 2003; 50 (9): 363-368.

  21. Merino PM, Schulin-Zeuthen C, Cannoni BG, Conejero RC. Síndrome de ovario poliquístico: diagnóstico en la adolescencia. Rev Med Clin Condes. 2015; 26 (1): 88-93.

  22. Lobo R. A., Carmina E. The Importance of Diagnosing the Polycystic Ovary Syndrome. Ann Intern Med. 2000; 132: 989-993.

  23. Hernández Valencia Marcelino, Hernández Rosas Marion, Zárate Arturo. Atención de la resistencia a la insulina en el síndrome de ovarios poliquísticos. Ginecol Obstet Mex 2010; 78(11): 612-616.

  24. Sabán M, Soutelo MJ, Lutfi JR. Metabolismo de los hidratos de carbono en el síndrome de ovario poliquístico. Rev Argent Endocrinol Metab. 2012; 49: 82-87.

  25. Fonseca-Villanea C. Síndrome de ovario poliquístico. Revista Médica Sinergia. 2018; 3(6): 9-15.

  26. Rodríguez-Flores M. Síndrome de ovario poliquístico: el enfoque del internista. Med Int Mex. 2012; 28 (1): 47-56.

  27. Del Castillo-Tirado F, Martínez-Ortega A, Del Castillo-Tirado R. Guía de práctica clínica de síndrome de ovario poliquístico. Archivos de Medicina. 2014; 10 (2-3). doi: 10.3823/1216.

  28. Morán C, Hernández M, Cravioto MC, Porias HL, Malacara JM, Bermúdez JA. Síndrome de ovario poliquístico. Posición de la Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrinol Nutr. 2006; 14 (1): 7-12.

  29. Escobar-Morreale HF. Etiología del síndrome del ovario poliquístico. Endocrinol Nutr. 2006; 53 (1): 7-14.

  30. Coviello AD, Legro RS, Dunaif A. J Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. Clin Endocrinol Metab. 2006; 91 (2): 492-497.

  31. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013; 6: 1-13.

  32. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016; 37 (5): 467-520.

  33. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015; 36 (5): 487-525.

  34. Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009; 24 (7): 1548-5155.

  35. Welt CK, Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013; 98 (12): 4629-4638.

  36. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. J Pediatr. 2013; 162 (5): 937-941.

  37. López-Iñiguez A. Síndrome de ovario poliquístico. Rev Med MD. 2010; 1.2 (6): 11-18.

  38. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes (Lond). 2007; 31 Suppl 2: S8-13; discussion S31-S32.

  39. Vargas-Carrillo MA, Sánchez-Buenfil G, Herrera-Polanco J, Vargas-Ancona L. Síndrome de ovarios poliquísticos: abordaje diagnóstico y terapéutico. Rev Biomed. 2003; 14 (3): 191-203.

  40. Vivas CA, Castaño-Trujillo P, García-Trujillo G, Ospina-Gutiérrez ML. Síndrome de ovario poliquístico. Fisiopatología en mujeres obesas y no obesas. Rev CES Med. 2011; 25 (2): 169-180.

  41. Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010; 89 (2): 199-204.

  42. Jiménez-López J, Olloqui-Escalona A, Díez-Álvarez A. El ovario poliquístico y las enfermedades dermatológicas. Más Dermatol. 2017; 28: 4-14.

  43. de la Jara-Díaz J, Ortega-González C. Síndrome de ovario poliquístico. Rev Mex Reprod. 2011; 4 (2): 51-62.

  44. Vázquez-Niebla JC, Calero-Ricardo JL, Carías JP, Monteagudo-Peña G. Correspondencia clínica, hormonal y ecográfica en el diagnóstico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2016; 27 (1): 4-17.

  45. Hardy TS, Norman RJ. Diagnosis of adolescent polycystic ovary syndrome. Steroids. 2013; 78 (8): 751-754.

  46. Escobar-Morreale HF, Alpañés-Buesa M, Álvarez-Blasco F, Luque-Ramírez M. Hiperandrogenismo y síndrome de ovario poliquístico. Medicine. 2012; 11 (15): 895-903.

  47. Gutiérrez C, Lozano-Hernández R, Lozano CA, Villavicencio A. Tensión arterial y masa corporal en mujeres infértiles con síndrome de ovario poliquístico y su relación con el perfil hormonal. Rev Obstet Ginecol Venez. 2014; 74 (3): 170-176.

  48. Ashrafi M, Sheikhan F, Arabipoor A, Hosseini R, Nourbakhsh F, Zolfaghari Z. Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). Eur J Obstet Gynecol Reprod Biol. 2014; 181: 195-199.

  49. Yang Y, Qiao J, Li R, Li MZ. Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol. 2011; 9: 7. doi: 10.1186/1477-7827-9-7.

  50. Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015; 7: 745-763.

  51. Capecce E, Pelanda M, Dicugno M, González de Sampaio E, Buongiorno G, Corazza N et al. La hormona antimülleriana como marcador de función ovárica. Rev Argent Endocrinol Metab. 2016; 53 (3): 106-113.

  52. Tehrani FR, Solaymani-Dodaran M, Hedayati M, Azizi F. Is polycystic ovary syndrome an exception for reproductive aging? Hum Reprod. 2010; 25 (7): 1775-1781.

  53. Park HT, Cho GJ, Ahn KH, Shin JH, Kim YT, Hur JY et al. Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010; 72 (1): 26-31.

  54. Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014; 31 (2): 213-220.

  55. Mora-Pérez J, Ibáñez-Hernández L, Paredes-Palma J. C. Prevalencia de síndrome de ovario poliquístico en pacientes con cáncer de mama y diabetes ¿posible factor de riesgo? Rev Esp Méd Quir 2012; 17 (4): 266-272.

  56. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010; 21 (12): 2303-2308.

  57. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014; 20 (5): 748-758.

  58. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352 (12): 1223-1236.

  59. Stener-Victorin E, Holm G, Janson PO, Gustafson D, Waern M. Acupuncture and physical exercise for affective symptoms and health-related quality of life in polycystic ovary syndrome: secondary analysis from a randomized controlled trial. BMC Complement Altern Med. 2013; 13: 131.

  60. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8: 41.

  61. Padmanabhan V. Polycystic ovary syndrome—”A riddle wrapped in a mystery inside an enigma”. J Clin Endocrinol Metab. 2009; 94 (6): 1883-1885.

  62. Gómez-Acosta C, Vinaccia-Alpi S, Quiceno-Japcy M. El síndrome de ovario poliquístico: aspectos psicológicos. Rev Chil Obstet Ginecol. 2015; 80 (4): 341-347.

  63. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 89 (11): 5454-5461.

  64. Christensen SB, Black MH, Smith N, Martinez MM, Jacobsen SJ, Porter AH et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril. 2013; 100 (2): 470-477.

  65. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16 (4): 347-363.

  66. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98 (12): 4565-4592.

  67. Enzevaei A, Salehpour S, Tohidi M, Saharkhiz N. Subclinical hypothyroidism and insulin resistance in polycystic ovary syndrome: is there a relationship? Iran J Reprod Med. 2014; 12 (7): 481-486.




2020     |     www.medigraphic.com